Table 4.
Efficacy of third‐line treatments
| Arm A (n = 40) | Arm B (n = 46) | Arm C (n = 34) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Third‐line chemotherapy | |||||||||
| None | 7 | 17.5% | 30 | 65.2% | 34 | 100% | |||
| FOLFOX | 17 | 42.5% | — | — | |||||
| CapeOX | 16 | 40.0% | — | — | |||||
| Cetuximab plus irinotecan | — | 12 | 26.1% | — | |||||
| Cetuximab monotherapy | — | 4 | 8.7% | — | |||||
| Treatment response | (n = 33) | (n = 16) | |||||||
| CR | 0 | 0.0% | 0 | 0.0% | — | ||||
| PR | 3 | 9.1% | 3 | 18.8% | — | ||||
| SD | 17 | 51.5% | 7 | 43.8% | — | ||||
| PD | 10 | 30.3% | 6 | 37.5% | — | ||||
| NA | 3 | 9.1% | 0 | 0.0% | — | ||||
| ORR (95% CI) | 9.1% (0.0–18.9) | 18.8% (0.0–37.9) | — | ||||||
| PFS‐3, median (95% CI) | 4.0 months (3.2–4.8) | 2.5 months (0.0–5.5) | — | ||||||
| OS‐3, median (95% CI) | 11.7 months (8.0–15.4) | 6.0 months (4.8–7.2) | — | ||||||
CapeOX, oxaliplatin/capecitabine; CI, confidence interval; CR, complete response; FOLFOX, oxaliplatin/5‐fluorouracil/leucovorin; NA, response evaluation was not available; ORR, overall response rate; OS‐3, overall survival from third‐line treatments; PD, progressive disease; PFS‐3, progression‐free survival from third‐line treatments; PR, partial response; SD, stable disease; –, not applicable.